Atelerix’s products are used for the storage and transportation of human cells and tissues at room temperature, removing the risk for cell degradation or damage.

NVL’s investment in the company coincides with an extremely challenging time for the UK economy, which is expected to enter recession as a result of the Covid-19 pandemic. Despite this unsettling economic backdrop Avantika Gupta, NVL’s Associate Investment Director notes “Atelerix’s product, despite being at an early stage, has demonstrated very encouraging results when applied to the task of transporting cell therapies at room temperature. This promise provides us with confidence that the company can overcome the challenging medium-term economic outlook and create long term value for investors.”

Furthermore, in recent weeks Atelerix has responded to a call to arms from the UK government for the medical sector to assist local authorities in the roll out of mass Covid-19 testing. Atelerix responded to that call, and are now designing an innovative storage kit to preserve swab samples at room temperature to extend the viability of testing samples beyond 72 hours (up to two weeks). This not only has immediate implications in the current global efforts in diagnosing Covid-19, but could be a monumental step to stabilising swab samples used to detect a plethora of diseases and conditions.

Atelerix CEO, Dr Mick McLean, comments “We are thrilled that the UK government has recognised the potential of our technology to be used in the fight against Covid-19. Extending the shelf life of viral swab samples contributes to the government’s goal of increasing daily testing for Covid-19 by allowing more patient samples to be collected so they can be safely stored for longer, or transported further afield to centralised testing facilities. To contribute to such an important project is something that the entire Atelerix team are delighted to be part of.”

For more information, please visit www.atelerix.co.uk. Mick McLean, CEO for Atelerix Ltd, can be contacted directly via mick.mclean@atelerix.co.uk.

This announcement has been produced using information provided by Atelerix

Your capital is at risk if you invest in early stage companies. These investments may not be covered by the Financial Services Compensation Scheme. Please see our risk statement here. Newable Ventures Limited (FRN 843924) is authorised and regulated by the Financial Conduct Authority. Registered in England and Wales | Registered number 10303336 | VAT number 237 9198 23 | Registered office 140 Aldersgate Street, London, EC1A 4HY.